Frequently Asked Questions > COVID-19 > Biospecimens

COVID-19 Biospecimens

Molecular Testing

Can I obtain detected and undetected COVID-19 residual waste specimens?

Yes.


Can I obtain cycle threshold (Ct) values with residual waste samples along with detected or undetected results?

Yes.


Since BioPharma Diagnostics uses a common code for COVID-19 testing, can I still obtain samples from a specific platform, or will the samples be a mix of platforms used for testing?

Samples tested by a specific platform are still available even though the common code is used. Available platforms can be discussed at the time of the request.


Can I specify a media type for residual waste media samples?

No. The media used is highly varied. However, all recommended media meets the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and Centers for Disease Control and Prevention (CDC) guidelines.


Can I receive symptom information and date of onset information with these samples?

No. The waste samples are de-identified. Therefore, we do not have symptom information.


What specimen types can I obtain?

Nasal, nasopharyngeal, and oropharyngeal specimens can be obtained.


Is saliva or stool available?

No.


Serology Testing

Can I obtain antibody positive and negative COVID-19 residual waste specimens?

Yes.


Can clinical information, such as date of positive PCR test, be provided with the sample?

No. These waste samples are de-identified. Therefore, we do not have clinical information such as date of positive PCR test or symptom information.


What method/platform is used for COVID-19 serology testing?

Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG, V 2.0


Is the assay used qualitative or quantitative?

The assay is qualitative. However, signal-to-cutoff (S/Co) ratio values can be provided.


Can I obtain signal-to-cutoff (S/Co) ratio values along with the antibody positive and negative results for these samples?

Yes.


What antibody type is measured? What is the antibody directed toward?

The Ortho Clinical Diagnostics assay is an IgG directed toward the SARS-CoV-2-spiked protein.


What other serology tests are available for residual specimens?

BioPharma Diagnostics has a qualitative serology antibody test that is total antibody and directed toward the SARS-CoV-2 nucleocapsid protein. This test is performed using the Roche Elecsys platform.